Rationale Several pre-clinical studies suggest that antipsychotic medications cause secondary negative symptoms. However, direct evidence for a relationship among antipsychotic medications, their direct effects on neurotransmitter systems, and negative symptoms in schizophrenia remains controversial. Objective The objective of this study was to examine the relationship between antipsychotic-related dopamine D 2/3 receptor occupancy and negative symptoms in patients with schizophrenia.
Introduction
Signs and symptoms such as affective flattening and amotivation, collectively termed negative symptoms (i.e., diminutions in normal behavior), represent prominent features of schizophrenia that characterize a sizeable number of patients (Kirkpatrick et al. 2006) . While these symptoms were described in patients long before the introduction of antipsychotic medications (Bleuler 1950; Kraepelin 1919) , it has also been suggested that negative symptoms are in some cases produced or worsened by antipsychotic drugs (Carpenter et al. 1988; Kelley et al. 1999; Schooler 1994) . This contention is bolstered by studies showing a worsening of negative symptoms following a single dose of antipsychotic medications in healthy volunteers (Artaloytia et al. 2006; Mas et al. 2013; Saeedi et al. 2006) , as well as pre-clinical investigations demonstrating reductions in motivation following administration of these drugs (Salamone and Correa 2012) . However, direct evidence for a relationship between antipsychotic medications, their direct effects on neurotransmitter systems, and negative symptoms in schizophrenia remains scarce.
In contrast to the aforementioned studies, clinical studies have shown that negative symptoms generally improve or do not substantially change following treatment with antipsychotic medications (Fusar-Poli et al. 2015; Leucht et al. 2009) , and withdrawal of these medications results in worsening of negative symptoms (Breier et al. 1987; Harvey et al. 1996; Miller et al. 1994; Weickert et al. 2003) . Several studies have failed to demonstrate a significant association between the severity of negative symptoms and the antipsychotic dosage (Fervaha et al. 2015a, b; Peralta et al. 2000; Prosser et al. 1987; Tugg et al. 1997) or plasma concentrations (Levinson et al. 1995; Marder et al. 2002; Prosser et al. 1987; Tugg et al. 1997) . Action at dopamine D 2 receptors (D 2 R) is the central feature of all antipsychotic drugs-all having antagonistic properties at this neuroreceptor (Kapur and Mamo 2003) . Studies examining the association between negative symptoms and antipsychotic D 2/3 R occupancy are limited. One previous study reported a positive relationship between antipsychotic striatal D 2/3 R occupancy and negative symptoms (de Haan et al. 2000) ; however, this finding was not replicated in a subsequent study (de Haan et al. 2003) . Another study also failed to observe higher antipsychotic D 2/3 R occupancy to be linked with greater negative symptom severity (Sakurai et al. 2013) , though the former variable was estimated from plasma drug concentrations rather than through molecular neuroimaging techniques. Notably, all the aforementioned investigations quantified negative symptoms utilizing the negative subscale of the Positive and Negative Syndrome Scale (PANSS) (Kay et al. 1987 ) which includes items tapping into cognitive impairments (e.g., difficulty in abstract thinking). This clearly complicates the interpretation of these past findings, especially as cognition itself has been associated with the antipsychotic dosage (Knowles et al. 2010) . Finally, studies to date have not explored the relationship between negative symptoms and antipsychotic occupancy in discrete subregions of the striatum including the ventral striatum, a region more closely associated with motivation than other striatal subregions (Haber and Knutson 2010) . Taken together, findings to date are inconclusive regarding the idea of antipsychoticinduced negative symptoms.
In the present study, we examined the relationship between antipsychotic D 2/3 R occupancy measured using carbon 11-labeled ([ 11 C])-raclopride and positron emission tomography (PET) and negative symptoms in schizophrenia. We explored this relationship in a sample of clinically stable outpatients with schizophrenia undergoing a protocolized reduction of their antipsychotic dose, which allowed for the examination of cross-sectional relationships as well as longitudinal interrelationships between D 2/3 R occupancy by antipsychotics and negative symptoms. Based on the aforementioned clinical studies, we hypothesized that we would fail to show a large and significant association between negative symptom severity and D 2/3 R occupancy by antipsychotics, i.e., higher antipsychotic-related D 2/3 R occupancy would not be positively correlated with levels of negative symptoms. Similarly, we hypothesized that there would be a lack of significant relationship between changes in occupancy and changes in negative symptom severity.
Methods and materials

Study design and participants
This study represents an extension of a previously reported prospective dose reduction PET study in patients with schizophrenia, for which the details and main results have been published elsewhere . Briefly, we recruited patients with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder, confirmed with the Structured Clinical Interview for DSM-IV Axis I Disorders (First et al. 2002) , aged 50 years or older, who were clinically stable (i.e., no inpatient hospitalization in the past 6 months) and receiving the same dose of risperidone or olanzapine monotherapy for at least 6 months. Patients receiving concomitant psychotropic medications were not excluded. Patients who met criteria for a substance use disorder within the past 6 months, had a urine drug screen positive for substances of abuse, had changed their dose of any psychotropic medication for mental health reasons within the past 6 months, or had an unstable medical condition were excluded.
The study was approved by the institutional Research Ethics Board, authorized by Health Canada, and registered at ClinicalTrials.gov (NCT00716755). All participants had to be deemed competent to provide consent as per the MacArthur Competence Assessment Tool for Clinical Research (Appelbaum and Grisso 2001) and provided written informed consent before the initiation of any study procedures.
Procedure
Participants were assessed with clinical scales for symptoms and adverse effects at baseline . A [ 11 C]-raclopride PET scan was performed to estimate antipsychotic D 2/3 R occupancy. Subsequently, participants underwent a gradual dose reduction of up to 40 % of their baseline dose or to the lower limit of the recommended dosage range (i.e., 7.5 mg/day for olanzapine and 1.5 mg/day for risperidone) (Alexopoulos et al. 2004 ). The dose was reduced weekly by 2.5 mg for olanzapine and 0.5 mg for risperidone. Clinical assessments and a [ 11 C]-raclopride PET scan were performed again at least 2 weeks after the final target dose was attained to ensure steady-state antipsychotic concentration in the brain. The participants were subsequently monitored for at least 3 months with clinical assessments. Clinical deterioration was defined as an increase of at least 20 % in the total Brief Psychiatric Rating Scale (BPRS) (Overall and Donald 1962) score from baseline.
On the same day of each of the two PET scans (baseline and post-dose reduction), participants' clinical status was evaluated using the PANSS (Kay et al. 1987) , and symptom scores were based on derived factors (Wallwork et al. 2012) . Medication-related side effects were evaluated using the Simpson-Angus Scale (SAS) (Simpson and Angus 1970) and the Barnes Rating Scale for Drug-Induced Akathisia (BAS) (Barnes 1989) , among other scales .
Negative symptom assessment
Severity of negative symptoms was evaluated using a consensus-defined factor from the PANSS (Wallwork et al. 2012) . Specifically, the following items were summed: blunted affect, emotional withdrawal, poor rapport, passive/ apathetic social withdrawal, lack of spontaneity and flow of conversation, and motor retardation. This negative symptom factor score from the PANSS has been shown to be highly convergent with more detailed measurements of negative symptoms including, for example, scores from the Scale for the Assessment of Negative Symptoms (van Erp et al. 2014) .
Given the burgeoning evidence for a two-factor structure of negative symptoms in schizophrenia (Messinger et al. 2011) , we also calculated two additional scores to evaluate amotivation and expressive deficits separately. Specifically, a social amotivation score was calculated by summing the following items from the PANSS: emotional withdrawal, passive apathetic withdrawal, and active social avoidance (Fervaha et al. 2014 ). This social amotivation score has been shown to have significant convergence with other measures of motivational deficits among patients with schizophrenia (Fervaha et al. 2015b; Luther et al. 2015) . A diminished expression score was also calculated by summing the following items from the PANSS: blunted affect, poor rapport, lack of spontaneity and flow of conversation, and motor retardation (Fervaha et al. 2014 ). Higher scores on each of these measures reflect greater severity of negative symptom.
Image acquisition and analysis
]-raclopride PET scans were carried out at baseline and again at least 2 weeks after the target antipsychotic dose was reached following dose reduction. The PET scans were performed 14-16 h after the last dose of the antipsychotic was given. Images were acquired using a high-resolution PET camera system (CPS-HRRT; Siemens Molecular Imaging, USA), which measures radioactivity in 207 brain slices with a thickness of 1.2 mm each. The in-plane resolution was ∼ 2.8 mm full-width at half-maximum (FWHM). Transmission scans were acquired using a single photon point source to provide attenuation correction ( 137 Cs; T 1/2 = 30.2 years, E = 662 KeV).
After each participant was placed on the scanning bed, a custom-fitted thermoplastic mask (True Scan Imaging) was made and then used during PET scans to decrease movement. A saline solution containing [ (Wilson et al. 2000) . The mean (SD) total mass injected, radioactivity dose, and specific activity of [ 11 C]-raclopride for the baseline and follow-up scans were 2.71 μg (1.96) and 2.95 μg (2.63), 9.69 mCi (0.79) and 9.65 mCi (0.72), and 1650.89 (701.51 mCi/μmol and 1549.84 mCi/μmol (711.59), respectively, without any significant differences between the 2 PET scanning sessions (paired-samples t test; P = 0.53, P = 0.65, and P = 0.38, respectively). Emission data were acquired in list mode for 60 min, reconstructed by filtered back projection, and redefined into 28 frames (1-5 of 1-min duration, 6-25 of 2-min duration, and 26-28 of 5-min duration).
Each participant also underwent three-dimensional, brain volume, T1-weighted magnetic resonance imaging (MRI; inversion time, 650 ms; field of view, 23 cm; 256 × 256; slice thickness, 0.9 mm; flip angle, 8°), performed in a GE Discovery MR750 3.0-T scanner (General Electric Medical Systems) to permit accurate delineation of the brain regions for data analysis. The region of interest (ROI)-based analysis for [
11 C]-raclopride has been described in detail elsewhere (Graff-Guerrero et al. 2008) . Briefly, time activity curves (TACs) from ROIs were obtained from the dynamic PET images in native space with reference to each subjects co-registered MRI image. The co-registration of each subject's MRI to PET space was done using the normalized mutual information algorithm (Studholme et al. 1997 ) as implemented in SPM2 (SPM2, Wellcome Department of Cognitive Neurology, London; http://www.fil.ion.ucl.ac.uk/spm). The TACs were analyzed using the simplified reference tissue method (SRTM) (Lammertsma and Hume 1996) , using the cerebellum as the reference region, to derive a quantitative estimate of binding: binding potential relative to the nondisplaceable compartment (BP ND ) as defined by the consensus nomenclature for in vivo imaging of reversibly binding radioligands (Innis et al. 2007 ). The basis function implementation of the SRTM (Gunn et al. 1997 ) was applied to the dynamic PET images to generate parametric voxelwise BP ND maps using PMOD (v2.7, PMOD Technologies, Zurich, Switzerland). These images were spatially normalized into Montreal Neurological Institute (MNI) brain space by Nearest Neighbor Interpolation with a voxel size fixed in 2 × 2 × 2 mm 3 using SPM2. Regional BP ND estimates were then derived from ROIs defined in MNI space. The ventral striatum and dorsal striatum (dorsal caudate, hereafter caudate and dorsal putamen, hereafter putamen) were defined according with Mawlawi et al. (2001) .
Calculation of occupancy
As we were not able to obtain BP ND data from our participants while they were off antipsychotics to compute D 2/3 R occupancy, we estimated participants' BP ND values using data from antipsychotic-free patients with schizophrenia. Specifically, age-and sex-corrected measures of BP ND were estimated for each ROI using a linear regression equation . D 2/3 R occupancy was calculated using the following formula:
where BP ND_Antipsychotic-free is the age-and sex-corrected BP ND derived from antipsychotic-free participants with schizophrenia, and BP ND_Medicated is the BP ND obtained from participants receiving oral risperidone or olanzapine.
Statistical analyses
Initially, a series of paired-samples t tests were carried out to evaluate whether there were any significant changes on any of the variables of interest following dose reduction (Table 2) . We then examined whether negative symptom severity in general was associated with antipsychotic-related D 2/3 R occupancy at baseline in a dose-dependent fashion using Spearman's rank correlations. We opted to employ Spearman's rank correlations rather than Pearson's product-moment correlations as the former evaluates both linear and non-linear dosedependent relationships, whereas the latter only evaluates linear relationships. D 2/3 R occupancy was examined in three striatal subregions (caudate, putamen, and ventral striatum) as well as within the whole striatum. After this, we explored whether such a relationship existed for the two discrete subdomains of negative symptoms. Subsequently, and for completeness, an exploratory item-level analysis was carried out. These analyses were repeated using the follow-up values. Finally, we examined whether changes in antipsychotic-related D 2/3 R occupancy following dose reduction were related to changes in negative symptom severity using Spearman's rank correlations. For this, difference scores were calculated for both symptom and occupancy values (score at follow-up minus the score at baseline). Notably, our study was powered to detect an association with a large effect size (i.e., 80 % power to detect a correlation coefficient greater than 0.4 at a two-tailed P value of 0.05), similar to that reported in one previous study (de Haan et al. 2000) .
We also defined prominent negative symptoms as a severity score of 4 (i.e., moderate) or greater on any of the individual negative symptom items comprising the negative symptom factor from the PANSS. Whether antipsychotic-related D 2/3 receptor occupancy differed for individuals with and without prominent negative symptoms at baseline was tested using an independent samples t test.
Statistical significance was set at P < 0.05 (two tailed), and analyses were carried out using SPSS version 20 (IBM Corporation, Armonk, NY).
Results
Participant characteristics
A total of 41 participants provided both clinical and PET data at baseline, and 38 participants provided follow-up data. Baseline sociodemographic and clinical characteristics of the 41 participants are presented in Table 1 . Eighteen participants (43.9 %) experienced at least one prominent negative symptom.
Negative symptoms before and after antipsychotic dose reduction
Findings from the majority of this sample have been reported previously . The three individuals (7.3 %) without follow-up PET data experienced clinical deterioration before reaching the target dose during the dose reduction phase of the study. For the other 38 participants with PET data at both time-points, the mean (SD) time to achieve the dose reduction was 2.2 weeks (1.5), and the time between the two PET scans was 6.5 weeks (2.3). Clinical and PET data before and after dose reduction are presented in Table 2 . Participants' doses were reduced by a mean (SD) of 34.2 % (4.1 %). After dose reduction, both the participants' antipsychotic dose and the corresponding D 2/3 R occupancy were significantly lower. Dose reduction was also associated with lower levels of antipsychotic-related motor side effects. In terms of symptom severity, negative symptoms were slightly, though not statistically significantly, lower following dose reduction; however, in an exploratory analysis using negative symptom subdomain scores, the severity of social amotivation was significantly lower following dose reduction, although the magnitude of change was modest and would not survive correction for multiple comparison testing (Table 2) . Notably, though, only 5 of the 39 participants (12.8 %) experienced a change in their social amotivation score over time, meaning that for the majority of participants, this symptom remained stable following antipsychotic dose reduction. Other symptoms did not significantly change following dose reduction.
Negative symptoms and dopamine D 2/3 receptor occupancy
At baseline, negative symptom severity was not associated with antipsychotic-related D 2/3 R occupancy in any striatal region (Table 3 ; Fig. 1 ). This finding held true for exploratory analyses with negative symptom subdomain scores and individual item scores. In fact, the magnitude for each bivariate relationship trended toward a negative association, whereby greater negative symptom severity was associated with lower occupancy. A similar pattern of results emerged at follow-up; there was no significant association between any negative symptom measure and occupancy in any striatal region (all Ps > 0.05).
For completeness, we also re-computed the above tests conducted with the full sample in the two subsamples of participants receiving either olanzapine or risperidone. The occupancy values did not differ between participants receiving olanzapine or risperidone (all P values >0.05). At baseline, a similar pattern of findings emerged for each drug group as that seen for the full sample; overall negative symptoms were not associated with antipsychotic-related D 2/3 R occupancy in any striatal region (all P values >0.05).
Participants with prominent negative symptoms at baseline did not differ from participants without such symptoms in terms of antipsychotic-related D 2/3 R occupancy in the caudate (t = 0.72, P = 0.47), putamen (t = 0.04, P = 0.97), ventral striatum (t = 0.48, P = 0.63), or whole striatum (t = 0.41, P = 0.68; Fig. 2) . Consistent with the dimensional analysis above, patients with prominent negative symptoms had lower mean occupancy values for all striatal regions, with the exception of the putamen where these values differed less than 0.2 %. The validity of the prominent negative symptom classification was underscored by the finding that these individuals had significantly more severe negative symptoms than individuals without prominent negative symptoms (t = 8.36, P < 0.001) but, importantly, did not differ in the severity of other symptom domains (all P values >0.05; Supplemental Table 1 ).
In the longitudinal subsample, changes in negative symptoms were not associated with changes in antipsychotic-related D 2/3 R occupancy in the caudate (r = 0.05, P = 0.79), putamen (r = 0.02, P = 0.90), ventral striatum (r = 0.15, P = 0.37), or whole striatum (r = 0.08, P = 0.64; Fig. 3) . A similar pattern of null findings emerged when examining the relationship between occupancy (Gardner et al. 2010) and negative symptom subdomain scores or individual items (all P values >0.05; Supplemental Table 2 ).
Discussion
The present study represents an extension of a previously reported dose reduction study , with analyses focused on negative symptom outcomes. The clinical results of the antipsychotic dose reduction echo those of our previous report in a smaller sample. Specifically, we show that antipsychotic dose can be successfully reduced in the majority of stable patients with schizophrenia who are receiving antipsychotic doses above the recommended minimum. Reduction of antipsychotic dose was associated with improvement in antipsychotic-related motor side effects in the face of stable symptoms (i.e., no substantial changes in symptoms were observed following antipsychotic dose reduction). The present analysis was carried out to examine the relationship, or lack thereof, between negative symptoms and antipsychotic D 2/3 R occupancy. To our knowledge, the present study is the largest PET study examining the relationship between antipsychotic occupancy of striatal D 2/3 R and negative symptoms, and the first to examine the inter-relationship between these variables in the context of a longitudinal dose reduction study, which provides the unique opportunity to explore the impact of changes in dopaminergic antagonism. We failed to find a relationship linking greater occupancy with greater burden of negative symptoms. In fact, the correlation coefficients of this association were in the opposite direction-i.e., greater negative symptoms were associated with lower occupancy, though this relationship was not significant. This bolsters our confidence that the absence of an association was not simply due to a lack of power, though we were adequately powered to detect a moderate to large effect size.
We also explored whether any relationship existed for specific negative symptoms and occupancy and, again, no significant relationship emerged. These lack of associations were seen in the face of a liberal type I error acceptance rate (i.e., α < 0.05, without correction for multiple comparison testing). All associations would, of course, be non-significant if a multiple comparison testing correction had been applied. We failed to find any dose-dependent relationship between negative symptoms and occupancy at both baseline and follow-up. Moreover, changes in antipsychotic occupancy level at striatal D 2/3 R were not related to changes in negative symptom severity. This latter finding is of particular importance as it suggests that after chronic stable treatment with antipsychotics, reduction in occupancy and, by inference, increases in dopaminergic transmission at D 2/3 R are not sufficient for improvement in negative symptoms. It should be noted that negative symptom severity did trend toward reduction following dose reduction, though the magnitude of this effect was modest. Moreover, the open-label design of the present study cannot rule out a nonspecific effect of time (i.e., a placebo effect); we cannot ascribe this nominal reduction in symptom severity to the reduction of antipsychotic dose rather than the benefits of ongoing treatment for example. Therefore, in light of these considerations, this finding should be interpreted with caution.
That no association was found between dopaminergic blockade (i.e., antagonism) at the D 2/3 R and negative symptoms in general, or motivational deficits in particular, is noteworthy as it stands in contrast to predictions based on preclinical investigations and the hypothesized role of dopamine-dependent neural circuitry in motivated behavior (Salamone and Correa 2012) . However, our findings are not b The dose of risperidone was converted to an olanzapine equivalent dosage, calculated using consensus-based antipsychotic dose equivalents based on Gardner et al. (2010) (20 mg olanzapine = 6 mg risperidone). The mean dose of olanzapine was 20.4 mg/day at baseline and 13.2 mg/day at follow-up (change P < 0.001), and the mean dose of risperidone was 4.5 mg/day at baseline and 2.9 mg/day at follow-up (change P < 0.001) inconsistent with these findings and do not rule out dopamine as an important mediator of negative symptoms. Instead, our findings suggest that there does not exist a systematic dosedependent relationship negative symptoms and occupancy (i.e., antagonism) of striatal D 2/3 R by antipsychotics. It is certainly possible that basal levels of striatal dopamine are implicated in negative symptom expression and there is, in fact, some evidence for this in schizophrenia (Kegeles et al. 2010) . At any rate, our findings reject the notion of dosedependent antipsychotic-induced negative symptoms. Other (non-iatrogenic) mechanisms need to be explored as causative agents in the expression of these symptoms. Our study also raises the question of why there was no observed relationship between negative symptoms and dopaminergic blockade. We speculate that several factors might be involved (Fervaha et al. 2015b) . Chief among these, we propose that differences in acute dosing paradigms used in preclinical and healthy volunteer studies and chronic dosing in patients with schizophrenia account for discrepancies. Some evidence supports that the effects of chronic treatment with antipsychotics are distinct from their acute effects (Amato et al. 2011; Samaha et al. 2007 ). Future pre-clinical studies are well positioned to resolve this question empirically, focusing on motivated behavior and examining potential neurobiological mechanisms. The present study examined variation in antipsychotic-related D 2/3 R occupancy of olanzapine and risperidone, two secondgeneration antipsychotic medications. Our study did not include an exhaustive list of other antipsychotic medications including first-generation and other second-generation drugs. While recent clinical data suggest that these two classes of antipsychotics do not substantially differ in terms of their effect on negative symptoms (Darbà et al. 2011; Fusar-Poli et al. 2015) , though see Zhang et al. (2013) , there exists evidence that these medication classes have distinct neurofunctional effects (Juckel et al. 2006; Lahti et al. 2009; Schlagenhauf et al. 2008 ). More specifically, there is some previous work suggesting that it is the first-generation, and not the second-generation, antipsychotics that are associated with reward system dysfunction and (secondary) negative symptoms (Juckel et al. 2006; Schlagenhauf et al. 2008 ). Thus, it is possible that a relationship between negative symptoms and dopaminergic blockade may be observed in a sample of patients treated with different antipsychotic medications. Data from a previous study that included patients receiving both olanzapine and haloperidol also failed to find a relationship between these two variables (de Haan et al. 2003) , arguing against the idea that a relationship necessarily exists when examining patients receiving first-generation antipsychotic medications.
The present study has limitations that should be mentioned. First, it did not include very high doses of antipsychotics, but rather included doses reflective of current practice which were within the range of consensus recommendations (Gardner et al. 2010) . Second, baseline medication dosing was not assigned randomly but, instead, determined based on realworld clinical decisions. Third, the present study employed a single-arm open-label study design over a few weeks. Thus the long-term effects of dose reduction or the non-specific effect of time on negative symptoms could not be assessed. However, previous research examining the clinical effects of antipsychotic dose reduction and employing a longer duration of follow-up has also failed to find significant changes in symptom severity (Harris et al. 1997) . Fourth, participants included in the study were aged 50 years and above; hence, the generalizability of our findings to younger patients or those with first-episode schizophrenia remains an open question. To this end, it should be underscored that our null findings are consistent with other PET studies in younger patients (de Haan et al. 2003) and that previous clinical studies have not found a significant relationship between patient age and negative symptoms (Schultz et al. 1997) . Fifth, we focused on antipsychotic occupancy of stiatal D 2/3 R given their centrality to the mechanism of action of these drugs (Kapur and Mamo 2003) and did not evaluate action at other neuroreceptors (e.g., dopamine D 1 , serotonin 5-HT 2A ) or extrastriatal regions (e.g., pre-frontal cortex). Sixth, our assessment of motivational deficits was incomplete. Our measure only evaluated this domain from one perspective (i.e., social amotivation), and we did not measure motivation for non-social goals. It would be of interest to discern whether objective tasks tapping into discrete aspects of negative symptoms are related to antipsychotic occupancy.
It has long been held that antipsychotic medications can induce secondary negative symptoms (Carpenter et al. 1988; Kelley et al. 1999; Schooler 1994) . However, direct evidence for this notion is limited. The present study failed to support this and instead suggests that there is no systematic relationship between antipsychotic occupancy at striatal D 2/3 R and severity of negative symptoms in schizophrenia. The lack of association was found for both overall and specific negative symptoms, including symptoms reflective of amotivation and diminished expression. Our results therefore suggest that antipsychotic-related dopaminergic antagonism does not necessarily undermine motivation and worsen expressive negative symptoms among stable patients receiving long-term treatment with these medications. It is possible that patients have adapted to the effects of these medications and compensate in some manner. In any case, we failed to find any robust evidence for a link between the effects of these drugs and negative symptoms.
